Advanced Oncotherapy plc (AVO.L)

1,9250 0,0000 (0,00%) Alla chiusura: 04:23PM BST

Advanced Oncotherapy plc

143 Harley street
Ground floor
London W1G 6BH
United Kingdom
44 20 3617 8728
https://www.avoplc.com

Settore/i: Healthcare
Settore: Medical Devices
Impiegati a tempo pieno: 174

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Michael Jeffrey Sinclair	Executive Chairman	434,42k	N/D	1942
Mr. Nicolas Serandour	CEO & Executive Director	502,96k	N/D	1975
Prof. Stephen Myers OBE	Executive Director	397,72k	N/D	1946
Mr. Ed Lee	COO & President of Europe	N/D	N/D	N/D
Mr. Graham Pughe	Senior Vice-President of Accounting	N/D	N/D	N/D
Ms. Berengere Pons-Chabord	Senior Vice-President of Corporate Finance	N/D	N/D	N/D
Mr. David Navas	Vice President of Investor and Public Relations	N/D	N/D	N/D
Ms. Bridget Biggar	Director of Human Resources	N/D	N/D	N/D
Ms. Donatella Ungaro	Managing Director of ADAM	N/D	N/D	N/D
Ms. Marina Giunta	Head of Physics Group	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in GBp.

Descrizione

Advanced Oncotherapy plc, together with its subsidiaries, engages in designing, assembling, and selling proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also engages in the management of healthcare related properties. It has operations in the United Kingdom, Switzerland, and the United States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy plc was founded in 1994 and is headquartered in London, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di Advanced Oncotherapy plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.